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Abstract 
Receptor tyrosine kinases (RTKs) are major regulators of key biological processes 
including cell growth, survival and differentiation, and were established early on as proto-
oncogenes, with aberrant expression linked to tumor progression in many cancers. Therefore, 
RTKs have emerged as major targets for selective therapy with small molecule inhibitors. 
However, despite improvements in survival rates, it is now apparent that targeting of RTKs 
with selective inhibitors is only transiently effective as the majority of patients eventually 
become resistant to therapy. As chemoresistance is the leading cause of cancer spread, 
progression and mortality, there is an increasing need for understanding the mechanisms by 
which cancer cells can evade therapy-induced cell death. The TAM (Tyro3, Axl, Mer) 
subfamily of RTKs in particular feature in a variety of cancer types that have developed 
resistance to a broad range of therapeutic agents, including both targeted as well as 
conventional chemotherapeutics. This article reviews the roles of TAMs as tumor drivers and 
as mediators of chemoresistance, and the potential effectiveness of targeting them as part of 
therapeutic strategies to delay or combat resistance.  
 
Introduction 
The TAM (Tyro3, Axl, MerTK) family of receptor tyrosine kinases (RTKs) is defined 
by each member possessing an extracellular combination of two immunoglobulin-like 
domains and two fibronectin type III repeats, a transmembrane portion, and an intracellular 
region with intrinsic tyrosine kinase activity. The human TAM genes share similar genomic 
structures, and their resulting proteins share significant structural similarities, with greatest 
homology in the tyrosine kinase domain. The apparent molecular weights range from 100-
140 kDa for Axl and Tyro3 and 165–205 kDa for MerTK due to post-translational 
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modifications, including glycosylation, phosphorylation and ubiquitination. The established 
natural ligands for the TAMs are two homologous vitamin K-dependent proteins, Gas6 (all 
three TAMs) and Protein S (Tyro3 and MerTK) (1).  
 
TAM functions 
All three TAMs have transforming potential; however, Axl overexpression has most 
frequently been detected in multiple cancers and its role in supporting tumorigenesis is well 
recognized. Axl supports tumour growth and dissemination through positive effects on cell 
survival, proliferation, migration, and invasion. Alongside these, Axl signaling is also 
involved in other processes ranging from the differentiation of cells in the erythroid lineage, 
protecting blood vessels from injury, clearance of apoptotic cells, angiogenesis, 
hematopoiesis, platelet aggregation and regulation of pro-inflammatory cytokine production 
(2, 3). MerTK is most distinctly recognized for its role in negative regulation of the immune 
system through to ability to mediate phagocytosis of apoptotic cells (4). Tyro3 has a more 
restricted tissue expression profile, and has been implicated in various roles including 
myelination in the brain (5).  
 
The TAMs as mediators of chemoresistance 
Although the TAMs are not strong oncogenes, it is increasingly clear that their 
overexpression contributes to acquiring resistance to both conventional as well as targeted 
chemotherapeutics in both solid and blood cancers. Early observations included increased 
Axl overexpression with resistance to the small molecule inhibitor imatinib (targets BCR-
Abl, c-Kit and PDGFR) in chronic myelogenous leukemia (CML) (6) and to the 
chemotherapy drugs doxorubicin, VP16 and cisplatin in acute myeloid leukemia (7). 
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Increased resistance to imatinib due to Axl and MerTK overexpression has also been reported 
in gastrointestinal stromal tumors (8) and non-small lung carcinoma (9).  
MerTK overexpression has been detected in high grade glioblastomas and its 
knockdown to result in increased sensitivity to etoposide whilst, conversely, control cells 
showed elevated MerTK activation upon DNA damage with increase resistance to etoposide 
(10). Inhibition of Axl and MerTK also lead to increased chemosensitivity to temozolomide, 
carboplatin and vincristine in astrocytoma (11), and to cisplatin and vincristine in 
neuroblastoma (12). Axl was also shown to promote resistance to ALK inhibitors in 
neuroblastoma through induction of epithelial-mesenchymal transition (EMT) (13). MerTK 
inhibition by a monoclonal antibody was able to increase sensitivity to carboplatin in non-
small cell lung cancer (NSCLC) due to receptor internalization and subsequent degradation 
which led to STAT6, Akt and ERK1/2 signaling inhibition (14). MerTK was also shown in 
NSCLC to be essential for increased resistance to erlotinib through the regulation of MAPK 
and FAK signaling pathways (15).  
Knockdown of Axl by short hairpin (sh)RNA has revealed Axl to promote the 
survival of cutaneous squamous carcinoma cells through Akt activation and inhibition of the 
pro-apoptotic Bcl-2 family proteins (16). Recently in melanoma, Tyro3 was identified to 
regulate expression of Microphthalmia-associated transcription factor (MITF), a master 
regulator of melanocyte development, and to promote tumorigenesis in spite of B-Raf-
induced senescence (17). Tyro3 was also shown to promote cell proliferation and 
chemoresistance in breast cancer (18). In addition, downregulation of both Axl and Tyro3 
was able to reverse taxol resistance in ovarian cancer (19).  
Increased Axl expression has also been associated with acquired resistance to 
selective EGFR small molecule inhibition. In lung cancers, this includes resistance to 
erlotinib through the induction of an EMT-like state (20), as well as to gefitinib (21). In 
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triple-negative breast cancer cells, expression of Axl was identified as a predictor for lack of 
response to lapatinib and erlotinib (22). Targeting EGFR antibodies such as cetuximab has 
also lead to resistance in NSCLC and head and neck carcinomas through Axl overexpression, 
via MAPK signaling (23). Such an association between EGFR and Axl molecular pathways 
also manifests itself through hetero-interaction between EGFR and Axl molecules, which can 
diversify downstream signaling pathways beyond those triggered by EGFR alone (24).  
The prominent expression and functions of TAM receptors across the immune system 
also suggests a potential role in mediating resistance to immune checkpoint inhibitors in 
cancer therapy. TAM receptors are notably expressed in many myeloid immune cells 
including macrophages and dendritic cells, and they may cooperate to create an 
immunosuppressive tumor microenvironment permissive to tumorigenesis (25). MerTK is 
implicated in the suppression of the M1 macrophage pro-inflammatory cytokine response, 
and Axl is required for the termination of Toll-like receptor dependent inflammatory response 
in dendritic cells (25). Also, the TAMs have been shown to negatively regulate NK cell 
functional maturation and normal expression of inhibitory and activating NK cell receptors 
(26). Furthermore, TAM receptors promote cancer metastases in vivo through suppression of 
NK cell activity, whilst treatment of wild-type NK cells with a TAM-selective small 
molecule inhibitor enhanced anti-metastatic NK cell activity (27). Collectively, these data 
implicate TAMs as key players in regulation of the innate immune system in the tumor 
microenvironment and indicate that their targeted inhibition will reverse the 
immunosuppressive microenvironment. This would in particular be expected to have an 
impact with use of immune checkpoint blockers in cancer therapy, e.g. inhibitors of CTLA-4, 
PD-1 or PD-L1. The TAMs, in particular MerTK, have been shown to upregulate the immune 
checkpoint molecule PD-L1 as well as promoting phosphatidylserine-dependent efferocytosis 
and Akt-mediated chemoresistance in tumor cells (28). Therefore, targeting TAM receptors 
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in combination with immune checkpoint blockers could both enhance the latter’s efficacy as 
well as combat eventual resistance. In support of this, recent data from mouse models of 
carcinoma showed the Axl inhibitor BGB324 in combination with immune checkpoint 
inhibitors to enhance tumour clearance, survival and tumour infiltration of cytotoxic T cells 
(29).  
Other influences that can contribute further to TAM-mediated tumor chemoresistance 
could include increased expression TAM ligands, although this is not clear. Gas6 expression 
has been identified as a marker for poor overall survival in ovarian cancer (30). Also, 
galectin-3, a sugar-binding protein that has been implicated in cancer cell behaviors (31), was 
indicated to be a novel ligand for MerTK (4). Axl expression has also been correlated with 
markers of DNA repair in different solid cancers; Axl inhibition induced reversal of EMT and 
decreased expression of DNA repair genes, rendering cancer cells sensitive to PARP 
inhibition in a synergistic manner (32).  
 
TAM inhibition to treat tumour drug resistance 
In addition to their roles in primary tumorigenesis, the prevalence of TAM receptors 
in patients displaying acquired drug-resistant tumors renders the TAMs a viable target for 
therapies against such evolved tumours. Importantly, TAM signaling inhibition sensitizes 
cells to chemotherapy, indicating that its effects are multifaceted, and the aim of “shutting 
down” multiple key biological processes in cancer cells can be achieved through a single 
target. A plethora of new, more specific and higher affinity targeting agents are currently 
under development (Table 1) that may prove to be effective for preventing, delaying or 
combating tumour drug resistance.  
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Table 1: TAM-selective inhibitors currently in development. All are small molecule 
inhibitors except YW327.6S2, which is a monoclonal antibody and GL21.T, which is an 
RNA aptamer.  
Name Target(s) Development stage 
DP3975 Axl Pre-clinical 
LDC1267 Axl, Tyro3, Mer Pre-clinical 
NA80x1 Axl Pre-clinical 
YW327.6S2 Axl Pre-clinical 
GL21.T Axl Pre-clinical 
NPS-1034 Axl, c-Met Pre-clinical 
UNC1062 Mer Pre-clinical 
UNC569 Mer Pre-clinical 
BGB324 Axl 
Phase I clinical trial for NSCLC 
(NCT02922777), AML 
(NCT02488408) and metastatic 
melanoma (NCT02872259) 
BMS777607 c-Met, Ron, Flt-3, Tyro3 Mer, Axl 
Phase I clinical trial for 
advanced and/or metastatic 
solid tumors (NCT01721148) 
Glesatinib (MGCD265) Axl, c-Met 
Phase II clinical trial for 
NSCLC patients with activating 
mutations in MET 
(NCT02544633). 
Sunitinib (SU11248) Flt-3, Axl, VEGFR-2, Kit 
Approved for pancreatic 
neuroendocrine and 
gastrointestinal stromal tumor 
and kidney cancer. 
Cabozantinib VEGFR-2, c-Met, Ret, Kit, Flt-3, Axl 
Approved for medullary thyroid 
cancer. 
 
A recent example is from a study that showed Axl to be upregulated in CML patients 
that had developed resistance to BCR-Abl small molecule inhibition, including through a 
T315I mutation in BCR-Abl. The selective Axl small molecule inhibitor BGB324 inhibited 
the resistant CML cells independent of BCR-Abl mutational status (33). This example 
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indicates an efficacious employment of Axl inhibition at the earliest signs of resistance 
development to first line or targeted therapies.  
 
Potential concerns about TAM inhibition 
The broad cellular and tissue expression profile of TAMs and their roles in the 
maintenance of the bodily organs’ normal functions should be a consideration in strategies 
aimed at inhibiting TAM receptors in cancer therapy. In particular, the role of TAMs in 
systemic immunity may represent a double-edged sword in terms of clinical outcome in 
strategies principally aimed at bolstering anti-tumor immunity. Both Axl and MerTK are 
expressed on multiple immune cells, such as dendritic cells and macrophages and have an 
essential immune-suppressive role via the abrogation of Toll-like receptor and cytokine 
receptor signaling. Sustained immune activation and chronic inflammation occurs in TAM 
triple knockout mice (34), and some cytokine receptor signaling systems appear co-dependent 
on TAM receptors (35). Additionally, one or more of the TAM receptors is a key gateway for 
phagocytic clearance of apoptotic cells or fragments, as observed in retinal degeneration due 
to MerTK impairment and hence defective uptake of photoreceptor outer segments by the 
retinal pigment epithelium (36). Experimental Mer blockade has also been shown to result in 
a greater proportion of dendritic cells with enhanced T cell activation capacity versus 
tolerogenic dendritic cells (37). Thus, prolonged TAM inhibition, through blocking clearance 
of dying cancer cells and their subsequent build-up, could result in adverse immune or 
inflammatory reactions beyond those specifically directed at the tumour cells. Also, Axl and 
MerTK double knockout mice displayed enhanced colitis resulting from insufficient 
neutrophil clearance (25), and an increased production of pro-inflammatory cytokines 
favoring a tumor-promoting environment with enhanced colonic polyps formation (38).  
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Results from current clinical trials with multikinase inhibitors including the TAMs 
(Table 1) already point to a weakened immune system and accumulation of lymphoid cells. 
This mirrors that which is observed in TAM knockout mice, in which activation of dendritic 
cells and macrophages also occurs, as well as clinical signs featured in autoimmune diseases 
such as rheumatoid arthritis and systemic lupus erythematosus (39). Therefore, therapeutic 
TAM targeting should consider carefully the possibility of inciting adverse pro-inflammatory 
effects that may conversely favor tumor promotion as opposed to a desired anti-tumor 
immune response. A particularly effective approach, which warrants clinical trial evaluation, 
would be TAM inhibition in combination with immune checkpoint blockade to target 
resistance as well as stimulate anti-tumour immunity specifically.  
The TAM RTKs represent a distinct grouping of novel anti-cancer targets through 
their promotion of tumor cell survival, proliferation, invasion and chemoresistance, as well as 
suppression of the immune status of the tumour microenvironment. Therefore, therapeutic 
TAM inhibition may sensitize tumor cells to killing by chemotherapy, radiation or other 
targeted agents and, in doing so, may create an even more robust innate immune response, 
which may enhance immunotherapeutic efficacy in combination with immune checkpoint 
inhibitors. Although development of autoimmunity is a consideration for any sustained TAM 
inhibition protocol, nevertheless the employment of novel selective TAM inhibitors has 
major potential moving forward in combating anti-cancer drug resistance for many solid and 
hematological malignancies.  
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